| E-Folder |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Team Building > Managing and Leading Great Teams |
|
E-Folder - Managing and Leading Great Teams
Warren Bennis is one of my favourite leadership thinkers. I first encountered his thinking in a book he co-authored with Burt Nanus, Lea According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ders: The Strategies for Taking Charge (1985). The book was based on in-depth interviews with 90 leaders, 60 from the corporate sector a ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in nd 30 from the public sector. Bennis and Nanus believe that the distinction between a manager and a leader is crucial. Both are essenti lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. al, but they are different. A manager brings things about, accomplishes things, and takes responsibility for conduct. A leader influenc here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe es and guides the opinion of the group, its direction, its course, and its action. “Managers are people who do things right,” they state d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro , “and leaders are people who do the right thing.” Managers tend to issues of efficiency, while leaders tend to issues of effectiveness. ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc As Bennis and Nanus went over the interviews and their notes, they distilled four major themes, four areas of competency, four types of easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi skills in working with humans that were shared by all 90 leaders. First, leaders of great teams focused the attention of their colleagu nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically es by articulating a compelling vision of the results possible. They constantly drew attention to desired outcomes. Their vision arose and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ from attentive listening to the needs of their customers and to the talents of their colleagues. It also challenged team members to offe ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi r their best. Their vision animated, inspired, and transformed purpose into action. Second, leaders of great teams created common meani ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ng through communication. Their careful listening allowed them to discover a powerful image around which they could organize the meaning dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod of what they were attempting to accomplish. They helped their colleagues know why their desired results were important. Third, leaders cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin of great teams gained the trust of their colleagues. “Trust,” wrote Bennis and Nanus, “is the lubrication that makes it possible for or tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ganizations to work.” Trust involved accountability, predictability, and reliability. Key is the behaviour of the leader. The actions t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel of trusted leaders embody and model the ideals of the vision. Fourth, leaders of great teams spend 90 percent of their time dealing with ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust the messiness of people issues. By developing a positive self-regard, by treating others with respect for their positive potential, and y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products by focusing on the capacity of everyone to embrace positive goals, leaders inspire the team to press forward in the achievement of their . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de compelling vision. What’s your unique blend of managing and leading? Are you paying attention to all four of those basic competencies elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip in human relationships in working with and through others? Your success in leading teams to greatness will be greatly enhanced if you do tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:
|